×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder

Become an Oncostream member and receive full access to its content!

You must be an Oncostream member to access videos without any restrictions. Register for free in one minute and access all services provided by Oncostream.You will also be able to log into Oncostream from your Facebook or twitter account by clicking on login on the top-right corner of Oncostream website.

Registration Login


Worldwide schedules comment Share
18:00
HRD, mutation BRCA : impact sur les décisions chirurgicales
Pr Fabrice Lécuru
 
18:20
Chimiothérapie ? Anti-angiogénique ? PARPi ? Quand et pour qui ?
Dr Manuel Rodrigues

18:40

La survie s’améliore. Et la qualité de vie ?
Pr Florence Joly

19:00 Débat/discussion - Réponses aux questions

 
Réunion modérée par Pr Fabrice Lécuru

Shooting date : 2021-02-10
Last update : 2022-02-14
1 comment
Join the Discussion
  • Lauriane G. Merci

      Please, select your files, click upload button, write your comment and click the send button. (allowed formats : images jpeg, gif, png, and PDF)
      Your browser doesn't have Flash, Silverlight or HTML5 support.


    Suggestions

    Tuesday, September 10th 2024 from 06pm to 07:30pm (GMT+2)
    Honolulu : Tuesday, September 10th 2024 from 07am to 08:30am (GMT+2)
    San Francisco : Tuesday, September 10th 2024 from 10am to 11:30am (GMT+2)
    New York : Tuesday, September 10th 2024 from 01pm to 02:30pm (GMT+2)
    Buenos Aires : Tuesday, September 10th 2024 from 02pm to 03:30pm (GMT+2)
    Reykjavik : Tuesday, September 10th 2024 from 05pm to 06:30pm (GMT+2)
    London / Dublin : Tuesday, September 10th 2024 from 06pm to 07:30pm (GMT+2)
    Paris / Berlin : Tuesday, September 10th 2024 from 07pm to 08:30pm (GMT+2)
    Istanbul : Tuesday, September 10th 2024 from 08pm to 09:30pm (GMT+2)
    Moscou / Dubaï : Tuesday, September 10th 2024 from 09pm to 10:30pm (GMT+2)
    Bangkok : Wednesday, September 11th 2024 from 12am to 01:30am (GMT+2)
    Shanghai : Wednesday, September 11th 2024 from 01am to 02:30am (GMT+2)
    Tokyo : Wednesday, September 11th 2024 from 02am to 03:30am (GMT+2)
    Sydney : Wednesday, September 11th 2024 from 04am to 05:30am (GMT+2)
    Wellington : Wednesday, September 11th 2024 from 06am to 07:30am (GMT+2)

    iPARP et cancer de l’ovaire : quand et pour qui ?

    Share
    0
    Days
    0
    Hours
    0
    Minutes
    0
    Seconds
    Wednesday, November 20th 2024 from 06pm to 07:30pm (GMT+1)
    Honolulu : Wednesday, November 20th 2024 from 07am to 08:30am (GMT+1)
    San Francisco : Wednesday, November 20th 2024 from 09am to 10:30am (GMT+1)
    New York : Wednesday, November 20th 2024 from 12pm to 01:30pm (GMT+1)
    Buenos Aires : Wednesday, November 20th 2024 from 02pm to 03:30pm (GMT+1)
    London / Dublin : Wednesday, November 20th 2024 from 05pm to 06:30pm (GMT+1)
    Paris / Berlin : Wednesday, November 20th 2024 from 06pm to 07:30pm (GMT+1)
    Istanbul : Wednesday, November 20th 2024 from 07pm to 08:30pm (GMT+1)
    Moscou / Dubaï : Wednesday, November 20th 2024 from 09pm to 10:30pm (GMT+1)
    Bangkok : Thursday, November 21st 2024 from 12am to 01:30am (GMT+1)
    Shanghai : Thursday, November 21st 2024 from 01am to 02:30am (GMT+1)
    Tokyo : Thursday, November 21st 2024 from 02am to 03:30am (GMT+1)
    Sydney : Thursday, November 21st 2024 from 03am to 04:30am (GMT+1)
    Wellington : Thursday, November 21st 2024 from 05am to 06:30am (GMT+1)

    Les iPARP dans le cancer de l’ovaire : biologie, rationnel, traitements actuels et perspectives...

    Monday, September 25th 2023 from 06:30pm to 08pm (GMT+2)
    Honolulu : Monday, September 25th 2023 from 07:30am to 09am (GMT+2)
    San Francisco : Monday, September 25th 2023 from 10:30am to 12pm (GMT+2)
    New York : Monday, September 25th 2023 from 01:30pm to 03pm (GMT+2)
    Buenos Aires : Monday, September 25th 2023 from 02:30pm to 04pm (GMT+2)
    Reykjavik : Monday, September 25th 2023 from 05:30pm to 07pm (GMT+2)
    London / Dublin : Monday, September 25th 2023 from 06:30pm to 08pm (GMT+2)
    Paris / Berlin : Monday, September 25th 2023 from 07:30pm to 09pm (GMT+2)
    Istanbul : Monday, September 25th 2023 from 08:30pm to 10pm (GMT+2)
    Moscou / Dubaï : Monday, September 25th 2023 from 09:30pm to 11pm (GMT+2)
    Bangkok : Tuesday, September 26th 2023 from 12:30am to 02am (GMT+2)
    Shanghai : Tuesday, September 26th 2023 from 01:30am to 03am (GMT+2)
    Tokyo : Tuesday, September 26th 2023 from 02:30am to 04am (GMT+2)
    Sydney : Tuesday, September 26th 2023 from 04:30am to 06am (GMT+2)
    Wellington : Tuesday, September 26th 2023 from 06:30am to 08am (GMT+2)

    Les scores indispensables dans la prise en charge des cancers de l'ovaire

    Cycle d'enseignement - Les cancers gynécologiques

    Share
    Wednesday, January 31st 2024 from 06pm to 07:30pm (GMT+1)
    Honolulu : Wednesday, January 31st 2024 from 07am to 08:30am (GMT+1)
    San Francisco : Wednesday, January 31st 2024 from 09am to 10:30am (GMT+1)
    New York : Wednesday, January 31st 2024 from 12pm to 01:30pm (GMT+1)
    Buenos Aires : Wednesday, January 31st 2024 from 02pm to 03:30pm (GMT+1)
    London / Dublin : Wednesday, January 31st 2024 from 05pm to 06:30pm (GMT+1)
    Paris / Berlin : Wednesday, January 31st 2024 from 06pm to 07:30pm (GMT+1)
    Istanbul : Wednesday, January 31st 2024 from 07pm to 08:30pm (GMT+1)
    Moscou / Dubaï : Wednesday, January 31st 2024 from 09pm to 10:30pm (GMT+1)
    Bangkok : Thursday, February 1st 2024 from 12am to 01:30am (GMT+1)
    Shanghai : Thursday, February 1st 2024 from 01am to 02:30am (GMT+1)
    Tokyo : Thursday, February 1st 2024 from 02am to 03:30am (GMT+1)
    Sydney : Thursday, February 1st 2024 from 03am to 04:30am (GMT+1)
    Wellington : Thursday, February 1st 2024 from 05am to 06:30am (GMT+1)

    KELIM ou comment optimiser l’utilisation du CA 125 dans la prise en charge du cancer de l’ovaire...

    Share